https://www.selleckchem.com/products/sodium-ascorbate.html To evaluate the diagnostic value of computer-aided diagnosis (CAD) software on ultrasound in distinguishing benign and malignant breast masses and avoiding unnecessary biopsy. This prospective, multicenter study included patients who were scheduled for pathological diagnosis of breast masses between April 2019 and November 2020. Ultrasound images, videos, CAD analysis, and BI-RADS were obtained. The AUC, accuracy, sensitivity, specificity, PPV, and NPV were calculated and compared with radiologists. Overall, 901 breast masses in 901 patients were enrolled in this study. The accuracy, sensitivity, specificity, PPV and NPV of CAD software were 89.6%, 94.2%, 87.0%, 80.4%, and 96.3, respectively, in the long-axis section; 89.0%, 91.4%, 87.7%, 80.8%, and 94.7%, respectively, in the short-axis section. With BI-RADS 4a as the cut-off value, CAD software has a higher AUC (0.906 vs 0.734 vs 0.696, all p < 0.001) than both experienced and less experienced radiologists. With BI-RADS 4b as the cut-off value, CADials.gov (NCT03887598) KEY POINTS • Prospective multicenter study showed that computer-aided diagnosis software provides greater diagnostic confidence for differentiating benign and malignant breast masses. • Computer-aided diagnosis software can help radiologists reduce unnecessary biopsy. • The management of patients with breast masses becomes more appropriate. To investigative the performance of intratumoral and peritumoral radiomics based on contrast-enhanced spectral mammography (CESM) to preoperatively predict the effect of the neoadjuvant chemotherapy (NAC) of breast cancers. A total of 118 patients with breast cancer who underwent preoperative CESM and NAC from July 2017 to June 2020 were retrospectively analyzed, and the patients were grouped into training (n= 81) and test sets (n= 37) according to the CESM examination time. NAC effect for each patient was assessed by pathology. Intratumoral and peritumo